BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 20195654)

  • 1. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
    Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Fang F; Zheng M; Chen Z
    Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A live bivalent influenza vaccine based on a H9N2 virus strain.
    Wu R; Guan Y; Yang Z; Chen J; Wang H; Chen Q; Sui Z; Fang F; Chen Z
    Vaccine; 2010 Jan; 28(3):673-80. PubMed ID: 19892041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein.
    Guo L; Zheng M; Ding Y; Li D; Yang Z; Wang H; Chen Q; Sui Z; Fang F; Chen Z
    Arch Virol; 2010 Nov; 155(11):1765-75. PubMed ID: 20652335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice.
    Chowdhury MY; Seo SK; Moon HJ; Talactac MR; Kim JH; Park ME; Son HY; Lee JS; Kim CJ
    Virol J; 2014 Feb; 11():21. PubMed ID: 24502341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
    Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines.
    Ernst WA; Kim HJ; Tumpey TM; Jansen AD; Tai W; Cramer DV; Adler-Moore JP; Fujii G
    Vaccine; 2006 Jun; 24(24):5158-68. PubMed ID: 16713037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice.
    Xie H; Liu TM; Lu X; Wu Z; Belser JA; Katz JM; Tumpey TM; Ye Z
    J Infect Dis; 2009 Dec; 200(12):1874-83. PubMed ID: 19909080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice.
    Qiu M; Fang F; Chen Y; Wang H; Chen Q; Chang H; Wang F; Wang H; Zhang R; Chen Z
    Biochem Biophys Res Commun; 2006 May; 343(4):1124-31. PubMed ID: 16580631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of inactivated vaccine against H5N1 influenza virus infection in mice with type 1 diabetes.
    Wu J; Zhang F; Fang F; Chang H; Wang F; Yang Z; Sun B; Chen Z
    Vaccine; 2010 Mar; 28(15):2775-81. PubMed ID: 20117261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
    Zhao G; Du L; Xiao W; Sun S; Lin Y; Chen M; Kou Z; He Y; Lustigman S; Jiang S; Zheng BJ; Zhou Y
    Vaccine; 2010 Oct; 28(44):7233-40. PubMed ID: 20732469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge.
    Wang X; Zhang W; Liu F; Zheng M; Zheng D; Zhang T; Yi Y; Ding Y; Luo J; Dai C; Wang H; Sun B; Chen Z
    Arch Virol; 2012 Aug; 157(8):1451-61. PubMed ID: 22552485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
    Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
    Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice.
    Zhou H; Jin M; Yu Z; Xu X; Peng Y; Wu H; Liu J; Liu H; Cao S; Chen H
    Antiviral Res; 2007 Nov; 76(2):186-93. PubMed ID: 17719657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant.
    Zheng M; Liu F; Shen Y; Wang S; Xu W; Fang F; Sun B; Xie Z; Chen Z
    Hum Vaccin Immunother; 2015; 11(2):397-406. PubMed ID: 25607884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.